Abstract. Human Mob as tumor suppressor 1 (MATS1) has been shown to play a crucial role in tumor growth by regulating cell proliferation and apoptosis. We evaluated the expression of MATS1 in colorectal cancer patients and assessed its clinicopathological significance. MATS1 mRNA expression in paired tumor/normal samples from 72 cases of colorectal cancer was evaluated, using real-time RT-PCR analysis. MATS1 protein expression was determined by immunohistochemical staining. MATS1 mRNA expression was significantly lower in tumor tissues than in normal colorectal tissues (p<0.05). Clinicopathologically, factors such as incidence of large tumor size, deep invasion, lymphatic permeation and liver metastasis were significantly more frequent in the low MATS1 expression group (p<0.05). Prognosis of the low expression group tended to be poorer than that of the high expression group. MATS1 protein expression was diminished in tumor cells compared with corresponding non-cancer colon epithelial cells. MATS1 mRNA expression is suppressed in tumor tissue and its low expression is associated with tumor growth, invasion and metastasis of colorectal cancer. Specifically, low MATS1 expression may be a good marker of liver metastasis, a life-threatening indicator for colorectal cancer patients.
Introduction
Human Mob as tumor suppressor 1 (MATS1) is a homolog of Drosophila MATS (a member of the Mob protein superfamily) and was reported to be a novel tumor suppressor gene (1) . MATS1 interacts with one of the nuclear Dbf2-related (NDR) family members, large as tumor suppressor 1 (LATS1), and activates protein kinase activity of LATS1 (2, 3) . The mechanism of cell proliferation and apoptosis by LATS and MATS was elucidated in Drosophila (Fig. 1A) . The Hippo (Hpo) -Salvador (Sav) -LATS -MATS pathway functions to coordinate cell proliferation and cell death by regulating levels of key molecules such as Cyclin E (cell cycle accelerator) and DIAP1 (apoptosis inhibitor). These subsequently control organ size (4) (5) (6) . A similar mechanism was proposed for humans ( Fig. 1B) . Mammalian Ste20-like (MST2) and SAV1 are human homologs of Drosophila Hpo and Sav, respectively. The MST2 -SAV1 -LATS1 -MATS1 pathway also controls cell proliferation and apoptosis through key molecules such as CDC2 and BAX -HTRA2 (7) (8) (9) (10) (11) (12) . Imbalances in this pathway may therefore contribute to the development of tumors. Indeed, abnormal control of the LATS1 gene causes cancer (13) (14) (15) (16) (17) and loss of MATS1 expression causes human skin melanoma (1) . MATS1 expression has not been studied in human colorectal cancer.
We studied MATS1 gene expression in human colorectal cancer and showed that its expression was down-regulated in colorectal cancer tissue. Expression status was associated with several clinical and pathological factors, including liver metastasis.
Materials and methods

Clinical samples and laser micro-dissection samples.
A total of 72 patients with colorectal cancer (28 male, 44 female), who had surgery at our institutes between 1993 and 1999, were involved in the present study. Written informed consent was obtained from all patients. All 72 patients were clearly diagnosed with colorectal cancer based on clinicopathological criteria described by the Japanese Society for Cancer of the Colon and Rectum (18) . Resected tumor and paired non-tumor tissue specimens were immediately frozen in liquid nitrogen and kept at -80˚C until analysis. The tumor center in the resected specimen was extracted for examination, with care taken to avoid necrotic tissue. The tissues from eight of 72 patients with colorectal cancer were selected for laser microdissection (LMD). For LMD, 5-micron frozen sections were fixed in 70% ethanol for 30 sec, stained with hematoxylin and eosin and dehydrated as follows: 5 sec each in 70%, 95% and 100% ethanol and a final 5 min in xylene. Sections were air-dried, then micro-dissected with the LMD system (Leica Microsystems, Wetzlar, Germany). Target cells were excised, at least 100 cells per section, and bound to the transfer film.
Total RNA extraction. Frozen tissue specimens were homogenized in guanidinium thiocyanate and total RNAs were obtained by ultracentrifugation through a cesium chloride cushion as described previously (20, 21) . Cultured cells from each cell line were dissolved in 350 μl of buffer RLT containing 1% ß-mercaptoethanol and total RNA was extracted and purified using the RNeasy mini kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's protocols. supplemented with 10% fetal bovine serum (Equitec-Bio, Ingram, TX), 100 units/ml penicillin G and 100 μg/ml streptomycin (Invitrogen Corp.). The cells were incubated in 5% CO 2 at 37˚C and passaged every three days.
Real-time quantitative RT-PCR.
The sequences of MATS1 primers were as follows: sense primer, 5'-CCTCAACACC TCCTTTAAGCAC-3'; and antisense primer, 5'-AGACAC AGGCAATGGGTATCTT-3'. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control and the sequences of GAPDH primers were as follows: sense primer, 5'-TTGGTATCGTGGAAGGACTCTA-3'; and antisense primer, 5'-TGTCATATTTGGCAGGTT-3'. cDNA was synthesized from 8.0 μg of total RNA as described previously (22) . Real-time monitoring of PCR reactions was performed using the LightCycler™ system (Roche Applied Science, Indianapolis, IN) and SYBR-Green I dye (Roche Diagnostics). Monitoring was performed according to the manufacturer's instructions, as described previously (23, 24) . In brief, a master mixture was prepared on ice, containing 1 μl of cDNA, 2 μl of DNA Master SYBR-Green I mix, 50 ng of primers and 2.4 μl of 25 mM MgCl 2 . The final volume was adjusted to 20 μl with water. After the reaction mixture was loaded into the glass capillary tube, quantitative RT-PCR was performed with the following cycling conditions: initial denaturation at 95˚C for 10 min, followed by 32 cycles of 95˚C for 10 sec, annealing at 60˚C for 10 sec and extension at 72˚C for 10 sec. After amplification, products were subjected to a temperature gradient from 68˚C to 95˚C at 0.2˚C/sec, under continuous fluorescence monitoring, to produce a melting curve of the products.
Data analysis. Expression levels of MATS1 and GAPDH mRNA were determined by comparing with cDNA transcribed from Human Universal Reference total RNA (Clontech, Palo Alto, CA). After proportional baseline adjustment, the fit point method was employed to determine the cycle in which the log-linear signal was first distinguishable from the baseline. This cycle number was used as the crossing-point value. A standard curve was produced by measuring the crossing point of each standard value and plotting it against the logarithmic value of concentration. Concentrations of the unknown samples were calculated by plotting their crossing points against the standard curve and dividing by GAPDH content. GAPDH expression confirmed no differences between tumor and normal tissue.
Immunohistochemistry. Immunohistochemical studies for MATS1 were performed on formalin-fixed, paraffin-embedded surgical sections obtained from patients with colorectal cancer. Tissue sections were deparaffinised, soaked in 0.01 M sodium citrate buffer and boiled in a microwave for 5 min at 500 W to retrieve cell antigens. Primary antibodies against MATS1 (mouse monoclonal antibody provided by Professor Zhi-Chun Lai, Department of Biology, Department of Biochemistry and Molecular Biology, Pennsylvania State University) were incubated overnight at 4˚C. Tissue sections were immunohistochemically stained using the streptavidinbiotin peroxidase method (LSAB + system -HRP; Dako, Cat #K0690, Kyoto, Japan). All sections were counter-stained with hematoxylin. Statistics. For continuous variables, data was expressed as mean ± standard deviation. The relationship between MATS1 mRNA expression and clinicopathological factors was analyzed using the chi-square test and Student's t-test. Surviving curves were plotted according to the Kaplan-Meier method and the generalized log-rank test was applied to compare the survival curve. All tests were analyzed using JMP software (SAS Institute Inc., Cary, NC, USA) and the findings were considered significant when the p-value was <0.05.
Results
Expression of MATS1 mRNA in clinical LMD samples, tissue specimens and cell lines. We determined levels of MATS1 mRNA expression by comparing with a human universal reference quantifying standard, which expressed human MATS1 sufficiently. Mean expression levels of MATS1 in the cancerous portion of 8 patients' samples were significantly lower than levels in the non-cancerous part of the samples ( Fig. 2A;  p<0 .01, Student's t-test). MATS1 mRNA expression was also significantly lower in 8 human colon cancer cell lines. The mean expression level of MATS1 mRNA in tumor tissue specimens was significantly lower than that of non-tumor tissue ( Fig. 2B; p<0 .05, Student's t-test). No differences in mRNA expression level were found between non-tumor tissue and non-cancerous part (p=0.16).
MATS1 mRNA expression and clinicopathological characteristics. To investigate the clinical significance of MATS1
expression, the tumor (T)/normal (N) ratio of MATS1 mRNA expression was calculated in each case. We apportioned all 72 patients into two groups as follows: 25 cases into the high MATS1 expression group (T/N>1) and 47 cases into the low MATS1 expression group (T/N<1). The association between clinicopathological features and MATS1 mRNA expression is summarized in Table I (chi-square test). In the low MATS1 expression group, incidences of large tumor size, serosal invasion and positive lymphatic invasion were significantly increased compared to the high MATS1 expression group (p<0.05, p<0.01 and p<0.05, respectively). Also, the incidence of liver metastasis in the low MATS1 expression group was significantly higher than that in the high MATS1 expression Table I . MATS1 mRNA expression and clinicopathological factors. ------------------------------------------------ 
-------------------------------------------------
On the other hand, venous permeation was not associated with liver metastasis (p=0.23; Table II ). There was no significant difference in lymph node metastasis, however, there was a significant association (p<0.01) among Dukes A group and Dukes B, C and D groups. Other pathological variables, such as sex, age, histological grade, peritoneal dissemination and venous permeation, were not significantly different between the two groups. The 5-year actuarial diseasespecific survival ratios in the low MATS1 expression group and the high MATS1 expression group were 53.5% and 84.4%, respectively. Moreover, prognosis of the low MATS1 expression group was poor compared with the high MATS1 expression group in the Kaplan-Meier survival curve ( Fig. 3;  p=0 .06, log-rank test).
Immunohistochemistry of MATS1 expression. Expression of MATS1 protein was evaluated by immunohistochemistry of resected colorectal tissue specimens, using an anti-MATS1 antibody. Intracellular expression of MATS1 protein was remarkably stronger in non-cancerous colorectal cells than in the cancer cells (Fig. 4) .
Discussion
Disruption of the MST2 -SAV1 -LATS1 -MATS1 pathway is associated with cancer development. With respect to LATS1, Hisaoka et al studied human soft tissue sarcoma and reported that 7 of 50 tumors showed low or no expression of LATS1 due to hypermethylation of the promoter region in 6 tumors and a point mutation in the other (14) . Jiang et al studied 88
human astrocytomas and showed hypermethylation of the promoter region in 56 cases (17), while Takahashi et al reported hypermethylation of the promoter region in 60% of breast cancers. Cases with low or no expression of LATS1 mRNA showed larger tumor size, positive lymph node metastasis, or negative estrogen receptor and/or progesterone receptor. In addition, low expression of the gene was associated with patient prognosis and found to be an independent prognostic factor by multivariate analysis (15). Asaka et al studied lymph node-positive breast cancer, with or without recurrence, by cDNA microarray analysis and determined that LATS1 gene expression was suppressed in tumors with recurrence (16) . With respect to the MATS1 gene, only one study has been published, which reports the absence of MATS1 expression in some human skin melanomas or mouse mammary gland carcinomas. This was due to a three nucleotide deletion in the sixth or seventh codon for human melanomas or a 38-bp insertion, immediately downstream of the fifth codon, that caused a premature termination of the MATS1 gene in mouse carcinomas (1) .
Our current study determined that MATS1 gene expression was significantly suppressed in human colorectal cancer tissue compared to normal tissue. When mRNA expression levels in tumors and normal tissue were calculated, a statistically significant inverse correlation was found between the size of tumor and MATS1 expression. Therefore, we speculated that diminished expression of MATS1 in normal colorectal tissue suppressed LATS1 expression. This might cause disruption of the normal cell cycle and apoptotic mechanism and could accelerate carcinogenesis or promote proliferation of cancer cells.
According to the clinicopathological variables (Table I) , the group of tumors with low MATS1 expression tended to invade deeper into the wall and permeated lymphatic vessels more frequently than the group of tumors with high MATS1 expression. MATS1 expression was unrelated to the incidence of lymph node metastasis. However, the increased incidence of serosal invasion in cases with the low MATS1 expression determined the Dukes clinical stage. Therefore, low expression of MATS1 in human colorectal cancer was considered intimately associated with tumor invasion.
Cases with low MATS1 expression tended to indicate a poor prognosis compared to cases with high MATS1 expression. This may be because the number of cases with liver metastases at the time of the operation was larger in the low MATS1 expression group. Several reports have suggested that venous invasion of colorectal cancer is profoundly related to liver metastasis or prognosis (25) (26) (27) (28) (29) (30) (31) . However, in our study, low Table II . Relation of liver metastasis with MATS1 expression and venous permeation. ---------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------Figure 3 . Kaplan-Meier overall survival curves for the low MATS1 expression group and the high MATS1 expression group. The difference in overall survival rate between the two groups was not significant (p=0.06, log-rank test).
MATS1 expression was associated more with liver metastasis than positive venous invasion (Table II) . Therefore, low MATS1 expression in the primary tumor may be a good indicator of liver metastasis. As liver metastasis is one of the critical indicators that predicts a poor prognosis of colorectal cancer cases (32) , surgical resection of liver tumors is effective for extending the survival period of those patients (33, 34) . In other words, once the magnitude of MATS1 expression has been established, we can predict the likelihood of liver metastasis and treat patients accordingly.
In conclusion, the current study identifies and determines the clinical significance of MATS1 expression in human colorectal cancer cases. We found that MATS1 expression was diminished in malignant tissues compared to surrounding normal tissues and that cases of low MATS1 expression were significantly associated with increased tumor size, depth of tumor invasion, and incidences of lymphatic permeation. In addition, low expression of MATS1 may be a critical indicator for the prediction of liver metastasis in primary colorectal cancer cases. 
